Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Bethesda Neurology, LLC
mi
from
Bethesda, MD
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Bethesda Neurology, LLC
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Longwood Medical Eye Center
mi
from
Boston, MA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Longwood Medical Eye Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Atlantic Clinical Trials, Llc
mi
from
Watertown, MA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Atlantic Clinical Trials, Llc
mi
from
Watertown, MA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Henry Ford Health System
mi
from
Dearborn, MI
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Henry Ford Health System
mi
from
Dearborn, MI
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Neuro-Ophthalmic Services
mi
from
Royal Oak, MI
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Neuro-Ophthalmic Services
mi
from
Royal Oak, MI
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Minnesota Medical School
mi
from
Minneapolis, MN
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Minnesota Medical School
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
JFK Medical Center, NJ Neuroscience Institute
mi
from
Edison, NJ
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
JFK Medical Center, NJ Neuroscience Institute
mi
from
Edison, NJ
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Stony Brook University Medical Center
mi
from
East Setauket, NY
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Stony Brook University Medical Center
mi
from
East Setauket, NY
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
E.S. Harkness Eye Institute
mi
from
New York, NY
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
E.S. Harkness Eye Institute
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Pmg Research Of Salisbury
mi
from
Salisbury, NC
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Pmg Research Of Salisbury
mi
from
Salisbury, NC
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
The Ohio State University College of Medicine
mi
from
Columbus, OH
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
The Ohio State University College of Medicine
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Dr. Daniel Lin
mi
from
Oregon, OH
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Dr. Daniel Lin
mi
from
Oregon, OH
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Family Eye Care
mi
from
Lancaster, PA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Family Eye Care
mi
from
Lancaster, PA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Pennsylvania Hospital
mi
from
Philadelphia, PA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Pennsylvania Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Allegheny Ophthalmic and Orbital Associates
mi
from
Pittsburgh, PA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Allegheny Ophthalmic and Orbital Associates
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Retina Consultants of Charleston
mi
from
Charleston, SC
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Retina Consultants of Charleston
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Black Hills Regional Eye Institute
mi
from
Rapid City, SD
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Black Hills Regional Eye Institute
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Neuro-Opthalmology of Texas
mi
from
Houston, TX
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Neuro-Opthalmology of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Medical Center Ophthalmology Associates
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
University of Washington Medical Center
mi
from
Seattle, WA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Swedish Neuroscience Institute
mi
from
Seattle, WA
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Saint Louis University
mi
from
Saint Louis, MO
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated:  9/5/2017
Montefiore Medical Center
mi
from
The Bronx, NY
A Study to Determine if There is a Possible Association Between NAION and Phosphodiesterase Type 5 (PDE5) Inhibitors
A Prospective Case-crossover Study to Evaluate the Possible Association Between the Use of PDE5 Inhibitors and the Risk of Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Status: Enrolling
Updated: 9/5/2017
Montefiore Medical Center
mi
from
The Bronx, NY
Click here to add this to my saved trials
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Status: Enrolling
Updated:  9/5/2017
Duke University School of Medicine / Dept. of Ophthalmology (Duke Eye Center)
mi
from
Durham, NC
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration
Status: Enrolling
Updated: 9/5/2017
Duke University School of Medicine / Dept. of Ophthalmology (Duke Eye Center)
mi
from
Durham, NC
Click here to add this to my saved trials
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
A Single-Center, Double-Masked, Randomization, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Enrolling
Updated:  9/11/2017
Andover Eye Associates
mi
from
Andover, MA
A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
A Single-Center, Double-Masked, Randomization, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Enrolling
Updated: 9/11/2017
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Mountain View, CA
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Mountain View, CA
Click here to add this to my saved trials
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Jackson, MI
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Jackson, MI
Click here to add this to my saved trials
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
McAllen, TX
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
McAllen, TX
Click here to add this to my saved trials
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Austin, TX
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated:  9/11/2017
Clinical Research Facility
mi
from
Walnut Creek, CA
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration
Status: Enrolling
Updated: 9/11/2017
Clinical Research Facility
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution Compared to Its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season
Status: Enrolling
Updated:  9/13/2017
ORA Inc
mi
from
Andover, MA
Efficacy of AC-150 for the Treatment of Allergic Conjunctivitis in the Enviro-CAC™ Model
A Multi-Center, Randomized, Double-Masked Evaluation of the Efficacy of Cetirizine 0.1%/Fluticasone 0.005% Ophthalmic Solution Compared to Its Components and Vehicle in a Modified Conjunctival Allergen Challenge (CAC) Model During Pollen Season
Status: Enrolling
Updated: 9/13/2017
ORA Inc
mi
from
Andover, MA
Click here to add this to my saved trials
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Therapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Status: Enrolling
Updated:  9/14/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Therapeutic Clinical Trial of Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome
Status: Enrolling
Updated: 9/14/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated:  9/16/2017
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated: 9/16/2017
Charlotte Eye, Ear, Nose & Throat Associates
mi
from
Charlotte, NC
Click here to add this to my saved trials
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated:  9/16/2017
May Eye Care Center & Associates
mi
from
Hanover, PA
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated: 9/16/2017
May Eye Care Center & Associates
mi
from
Hanover, PA
Click here to add this to my saved trials
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated:  9/16/2017
School of Optometry, University of Alabama at Birmingham
mi
from
Birmingham, AL
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated: 9/16/2017
School of Optometry, University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated:  9/16/2017
Specialty Eyecare Group
mi
from
Kirkland, WA
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated: 9/16/2017
Specialty Eyecare Group
mi
from
Kirkland, WA
Click here to add this to my saved trials
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated:  9/16/2017
Clayton Eye Center
mi
from
Morrow, GA
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated: 9/16/2017
Clayton Eye Center
mi
from
Morrow, GA
Click here to add this to my saved trials
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated:  9/16/2017
Centre for Contact Lens Research
mi
from
Waterloo,
Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers
Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers
Status: Enrolling
Updated: 9/16/2017
Centre for Contact Lens Research
mi
from
Waterloo,
Click here to add this to my saved trials
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion
Status: Enrolling
Updated:  9/17/2017
Texas Retina Associates
mi
from
Dallas, TX
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab for Central Retinal Vein Occlusion
Effect of Ozurdex® 0.7 mg on Improvement of Efficacy of Bevacizumab Therapy for Non-Ischemic Central Retinal Vein Occlusion
Status: Enrolling
Updated: 9/17/2017
Texas Retina Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Status: Enrolling
Updated:  9/21/2017
Golden Optometric Group
mi
from
Whittier, CA
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Status: Enrolling
Updated: 9/21/2017
Golden Optometric Group
mi
from
Whittier, CA
Click here to add this to my saved trials
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Status: Enrolling
Updated:  9/21/2017
Complete Eye Care of Medina
mi
from
Medina, MN
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Status: Enrolling
Updated: 9/21/2017
Complete Eye Care of Medina
mi
from
Medina, MN
Click here to add this to my saved trials
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Status: Enrolling
Updated:  9/21/2017
Brock & Houlford
mi
from
Chew Magna,
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses
Status: Enrolling
Updated: 9/21/2017
Brock & Houlford
mi
from
Chew Magna,
Click here to add this to my saved trials
Study of Ocular Penetration of Topically Administered Fluoroquinolones
Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery
Status: Enrolling
Updated:  9/21/2017
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
Study of Ocular Penetration of Topically Administered Fluoroquinolones
Parallel-group Study of Ocular Penetration of Peri-operative Topically Administered Fluoroquinolones With Cataract Surgery
Status: Enrolling
Updated: 9/21/2017
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis
Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis
Status: Enrolling
Updated:  9/22/2017
Truhlsen Eye Institute
mi
from
Omaha, NE
Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis
Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis
Status: Enrolling
Updated: 9/22/2017
Truhlsen Eye Institute
mi
from
Omaha, NE
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Stanford University
mi
from
Palo Alto, CA
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of California, San Diego
mi
from
San Diego, CA
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
Yale University
mi
from
New Haven, CT
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated:  9/22/2017
University of Miami
mi
from
Miami, FL
Surfactant Positive Airway Pressure and Pulse Oximetry Trial
Surfactant Positive Airway Pressure and Pulse Oximetry Trial (SUPPORT) in Extremely Low Birth Weight Infants
Status: Enrolling
Updated: 9/22/2017
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials